MMV533

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
MoA
  • Unknown, inability to select resistant mutants
Key features
  • Rapid parasite killing in vitro and clearance in vivo
  • Long predicted human half-life
  • Predicted dose to give coverage above Minimal Parasiticidal Concentration for >8 days is 80mg
Status
  • First-in-human study started
Next milestone
  • Complete phase I program (incl. volunteer infection study)
Previously
  • SAR 441121. Full reference name is MMV688533
MMV Project Director
  • Ilaria Di Resta